To investigate practical therapeutic methods to improve PCOS-like alterations and validate variation of Mtnr1a in the progress, we applied melatonin receptor agonist RMT and restored the normal light/dark circadian rhythm. The gene discussed is MTNR1A; the disease is polycystic ovary syndrome.